mupadolimab   Click here for help

GtoPdb Ligand ID: 11758

Synonyms: CPI-006 | CPI006 | CPX-006 [1] | CPX006
Compound class: Antibody
Comment: Mupadolimab (CPI-006) is a humanised IgG1-κ anti-CD73 (Ecto-5'-Nucleotidase; NT5E) monoclonal antibody that was developed by Corvus Pharmaceuticals as an immunostimulant, originally for oncology use. It functionally inhibits production of immunosuppressive adenosine in the tumour microenvironment, plus binding to CD73 on B cells leads to their activation (including increased antibody production). Corvus had initiated clinical investigation of mupadolimab for potential benefit in COVID-19 patients, but their phase 3 study was terminated, and as of mid-October 2021 there is no mention of this approach on their pipeline webpage (link here).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Mupadolimab (CPI-006) is under clinical investigation.

COVID-19: Corvus' phase 2 clinical trial in hospitalised patients with mild/moderate symptomatic COVID-19 was terminated with only 46 patients recruited.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04734873 CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients Phase 3 Interventional Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals terminated this study after only 46 participants were recruited.
NCT03454451 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Phase 1 Interventional Corvus Pharmaceuticals, Inc.
NCT04464395 Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients Phase 1 Interventional Corvus Pharmaceuticals, Inc.